Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.

Literature DB >> 26185406

Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.

Juan F Mosley, Lillian Smith, Emily Everton, Chris Fellner.

Abstract

Sodium-glucose linked transporter 2 inhibitors limit the reabsorption of glucose from glomerular filtrate in the kidneys, reducing blood glucose levels in patients with type- 2 diabetes. This article is meant to evaluate this class of medications for clinicians.

Entities: Chemical Disease Gene Species

Keywords: canagliflozin; dapagliflozin; empagliflozin; sodium-glucose linked transporter 2 (SGLT2) inhibitors; type-2 diabetes mellitus (T2DM)

Year: 2015 PMID： 26185406 PMCID： PMC4495872

Source DB: PubMed Journal: P T ISSN： 1052-1372

46 in total

Review 1. Physiology of glucose homeostasis.

Authors: J E Gerich
Journal: Diabetes Obes Metab Date: 2000-12 Impact factor: 6.577

2. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.

Authors: Eric Wooltorton
Journal: CMAJ Date: 2002-01-22 Impact factor: 8.262

Review 3. SGLT2 inhibition--a novel strategy for diabetes treatment.

Authors: Edward C Chao; Robert R Henry
Journal: Nat Rev Drug Discov Date: 2010-05-28 Impact factor: 84.694

4. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes.

Authors: Matthew M Riggs; Alexander Staab; Leo Seman; Thomas R MacGregor; Timothy T Bergsma; Marc R Gastonguay; Sreeraj Macha
Journal: J Clin Pharmacol Date: 2013-08-13 Impact factor: 3.126

5. SGLT2 mediates glucose reabsorption in the early proximal tubule.

Authors: Volker Vallon; Kenneth A Platt; Robyn Cunard; Jana Schroth; Jean Whaley; Scott C Thomson; Hermann Koepsell; Timo Rieg
Journal: J Am Soc Nephrol Date: 2010-07-08 Impact factor: 10.121

Review 6. Hyperglycemic crises in adult patients with diabetes.

Authors: Abbas E Kitabchi; Guillermo E Umpierrez; John M Miles; Joseph N Fisher
Journal: Diabetes Care Date: 2009-07 Impact factor: 17.152

7. Determination of Krebs cycle metabolic carbon exchange in vivo and its use to estimate the individual contributions of gluconeogenesis and glycogenolysis to overall glucose output in man.

Authors: A Consoli; F Kennedy; J Miles; J Gerich
Journal: J Clin Invest Date: 1987-11 Impact factor: 14.808

8. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

Authors: Bruce Neal; Vlado Perkovic; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Peter Stein; Mehul Desai; Wayne Shaw; Joel Jiang; Frank Vercruysse; Gary Meininger; David Matthews
Journal: Am Heart J Date: 2013-06-24 Impact factor: 4.749

9. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.

Authors: Bruce A Perkins; David Z I Cherney; Helen Partridge; Nima Soleymanlou; Holly Tschirhart; Bernard Zinman; Nora M Fagan; Stefan Kaspers; Hans-Juergen Woerle; Uli C Broedl; Odd-Erik Johansen
Journal: Diabetes Care Date: 2014-03-04 Impact factor: 19.112

10. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.

Authors: Hans-Ulrich Häring; Ludwig Merker; Elke Seewaldt-Becker; Marc Weimer; Thomas Meinicke; Hans J Woerle; Uli C Broedl
Journal: Diabetes Care Date: 2013-08-20 Impact factor: 19.112

19 in total

1. Sodium-Glucose Cotransporter 2 Inhibitor-Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review.

Authors: Ahmad Yehya; Archana Sadhu
Journal: Clin Diabetes Date: 2020-01

Review 2. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.

Authors: Maja Nikolic; Vladimir Zivkovic; Jovana Joksimovic Jovic; Jasmina Sretenovic; Goran Davidovic; Stefan Simovic; Danijela Djokovic; Nemanja Muric; Sergey Bolevich; Vladimir Jakovljevic
Journal: Heart Fail Rev Date: 2021-02-03 Impact factor: 4.214

3. Sodium-Glucose Cotransporter 2 Inhibitors and Euglycemic Diabetic Ketoacidosis: Metabolic Acidosis With a Twist.

Authors: Aala Jaberi; Bhavna Seth; Devin Steenkamp; Sara Alexanian; Steven C Borkan
Journal: Clin Diabetes Date: 2016-10

Review 4. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives.

Authors: Mathew John; Deepa Gopinath; Rejitha Jagesh
Journal: Indian J Endocrinol Metab Date: 2016 Jan-Feb

Review 5. Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

Authors: Vishal Gupta; William Canovatchel; B N Lokesh; Ravi Santani; Nishant Garodia
Journal: Indian J Endocrinol Metab Date: 2017 Nov-Dec

Review 6. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.

Authors: Serge Jabbour; Jochen Seufert; Andre Scheen; Clifford J Bailey; Cathrina Karup; Anna M Langkilde
Journal: Diabetes Obes Metab Date: 2017-10-26 Impact factor: 6.577

Review 7. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date.

Authors: Francesca Cinti; Simona Moffa; Flavia Impronta; Chiara Ma Cefalo; Vinsin A Sun; Gian Pio Sorice; Teresa Mezza; Andrea Giaccari
Journal: Drug Des Devel Ther Date: 2017-10-03 Impact factor: 4.162

Review 8. SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review.

Authors: Henri Lu; Hortense Lu; Christophe Kosinski; Anne Wojtusciszyn; Anne Zanchi; Pierre-Nicolas Carron; Martin Müller; Philippe Meyer; Jehan Martin; Olivier Muller; Roger Hullin
Journal: J Clin Med Date: 2021-05-10 Impact factor: 4.241

9. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.

Authors: Sam Tsz Wai Cheng; Lihua Chen; Stephen Yu Ting Li; Eric Mayoux; Po Sing Leung
Journal: PLoS One Date: 2016-01-25 Impact factor: 3.240

Review 10. Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?

Authors: Harriet Warnes; Rebecca Helliwell; Sam Matthew Pearson; Ramzi A Ajjan
Journal: Diabetes Ther Date: 2018-09-12 Impact factor: 2.945